Cel Meningiomas arise from arachnoid cells and account for approximately 30% of all primary intracranial tumors. Most meningiomas (80-90%) are categorized as benign tumors (WHO grade I), with the remaining 10-20% being atypical (WHO grade II) or malignant (WHO grade III). Gross total resection offers the best chance of cure. Unfortunately, for meningiomas that are difficult to access, complete resection often cannot be achieved safely. In patients whose tumors are incompletely resected, recurrence is common, approaching 70% with 10–15 years of follow-up; in the case of atypical and malignant meningiomas, the time to recurrence is shorter and long-term survival rates are low. There are no established treatments for recurrent meningioma when surgical and radiation options are exhausted and current experience with chemotherapy and various targeted therapies is disappointing. Therefore, novel therapeutic strategies which can be combined with surgery need to be developed to control tumor growth. This application is directed towards developing new therapeutic options for meningiomas in a high throughput small (HTS) molecule screening system using the NINDS custom collection II library consisting of 1040 drugs and bioactive compounds, FDA-approved, which cross the blood-brain barrier (BBB). In our primary screening, we identified drug candidates that were specifically toxic to meningioma cells. These promising preliminary data stimulate us to further evaluate the effect of these candidates on meningioma tumor models in mice and explore the possible molecular mechanism(s) of tumor inhibition mediated by these candidate drugs. Dziedzina nauki medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicinesurgery Program(-y) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Temat(-y) FP7-PEOPLE-2011-CIG - Marie-Curie Action: "Career Integration Grants" Zaproszenie do składania wniosków FP7-PEOPLE-2011-CIG Zobacz inne projekty w ramach tego zaproszenia System finansowania MC-CIG - Support for training and career development of researcher (CIG) Koordynator MEDIZINISCHE UNIVERSITAET WIEN Wkład UE € 100 000,00 Adres SPITALGASSE 23 1090 Wien Austria Zobacz na mapie Region Ostösterreich Wien Wien Rodzaj działalności Higher or Secondary Education Establishments Kontakt administracyjny Arnold Pollak (Prof.) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych
